Recent meaningful positive changes in fundamentals have benefitted ANI Pharmaceuticals Inc (NASDAQ: ANIP): the consensus estimate for December, 2025 increased significantly, the consensus estimate for December, 2024 increased significantly, and significant quarterly earnings acceleration occurred.
Recent notable positive changes in investment behavior have benefitted ANI Pharmaceuticals Inc (NASDAQ: ANIP): its longer term price trend turned up.
In light of these very positive signals we are reviewing our current Overall Rating of C. We would view the shares with optimism pending completion of this review in the next several days.
Current PriceTarget Research Rating
ANIP is expected to continue to be an important Value Builder reflecting capital returns that are forecasted to be above the cost of capital.
ANI Pharmaceuticals has a current Value Trend Rating of C (Neutral). This rating combines consistent signals from two proprietary PTR measures of a stock’s attractiveness. ANI Pharmaceuticals has a slightly positive Appreciation Score of 60 and a neutral Power Rating of 47, with the Neutral Value Trend Rating the result.
Recent Price Action
On 10/17/24, ANI Pharmaceuticals Inc (NASDAQ: ANIP) stock rose modestly by 0.8%, closing at $60.12. However, trading volume in this advance was exceptionally low at 42% of normal. The stock has risen 6.0% during the last week and has performed in line with the market over the last nine months.
Be the first to comment